Literature DB >> 31419796

Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system.

Hiroaki Takei1,2, Jun Shinoda1,3, Soko Ikuta4, Takashi Maruyama4, Yoshihiro Muragaki4, Tomohiro Kawasaki1,2, Yuka Ikegame1,3, Makoto Okada1, Takeshi Ito1, Yoshitaka Asano1,3, Kazutoshi Yokoyama1, Noriyuki Nakayama2, Hirohito Yano2, Toru Iwama2.   

Abstract

OBJECTIVE: Positron emission tomography (PET) is important in the noninvasive diagnostic imaging of gliomas. There are many PET studies on glioma diagnosis based on the 2007 WHO classification; however, there are no studies on glioma diagnosis using the new classification (the 2016 WHO classification). Here, the authors investigated the relationship between uptake of 11C-methionine (MET), 11C-choline (CHO), and 18F-fluorodeoxyglucose (FDG) on PET imaging and isocitrate dehydrogenase (IDH) status (wild-type [IDH-wt] or mutant [IDH-mut]) in astrocytic and oligodendroglial tumors according to the 2016 WHO classification.
METHODS: In total, 105 patients with newly diagnosed cerebral gliomas (6 diffuse astrocytomas [DAs] with IDH-wt, 6 DAs with IDH-mut, 7 anaplastic astrocytomas [AAs] with IDH-wt, 24 AAs with IDH-mut, 26 glioblastomas [GBMs] with IDH-wt, 5 GBMs with IDH-mut, 19 oligodendrogliomas [ODs], and 12 anaplastic oligodendrogliomas [AOs]) were included. All OD and AO patients had both IDH-mut and 1p/19q codeletion. The maximum standardized uptake value (SUV) of the tumor/mean SUV of normal cortex (T/N) ratios for MET, CHO, and FDG were calculated, and the mean T/N ratios of DA, AA, and GBM with IDH-wt and IDH-mut were compared. The diagnostic accuracy for distinguishing gliomas with IDH-wt from those with IDH-mut was assessed using receiver operating characteristic (ROC) curve analysis of the mean T/N ratios for the 3 PET tracers.
RESULTS: There were significant differences in the mean T/N ratios for all 3 PET tracers between the IDH-wt and IDH-mut groups of all histological classifications (p < 0.001). Among the 27 gliomas with mean T/N ratios higher than the cutoff values for all 3 PET tracers, 23 (85.2%) were classified into the IDH-wt group using ROC analysis. In DA, there were no significant differences in the T/N ratios for MET, CHO, and FDG between the IDH-wt and IDH-mut groups. In AA, the mean T/N ratios of all 3 PET tracers in the IDH-wt group were significantly higher than those in the IDH-mut group (p < 0.01). In GBM, the mean T/N ratio in the IDH-wt group was significantly higher than that in the IDH-mut group for both MET (p = 0.034) and CHO (p = 0.01). However, there was no significant difference in the ratio for FDG.
CONCLUSIONS: PET imaging using MET, CHO, and FDG was suggested to be informative for preoperatively differentiating gliomas according to the 2016 WHO classification, particularly for differentiating IDH-wt and IDH-mut tumors.

Entities:  

Keywords:  11C-choline; 11C-methionine; 18F-fluorodeoxyglucose; AA = anaplastic astrocytoma; AO = anaplastic oligodendroglioma; AUC = area under the curve; CHO = 11C-choline; DA = diffuse astrocytoma; DOR = diagnostic odds ratio; FDG = 18F-fluorodeoxyglucose; GBM = glioblastoma; IDH = isocitrate dehydrogenase; IDH-mut = mutant IDH; IDH-wt = wild-type IDH; MET = 11C-methionine; OD = oligodendroglioma; PET = positron emission tomography; R-2HG = R-2-hydroxyglutarate; ROC = receiver operating characteristic; ROI = region of interest; SUV = standardized uptake value; T/N = tumor maximal SUV/normal brain cortex mean SUV; glioma; isocitrate dehydrogenase mutation; oncology; positron emission tomography

Year:  2019        PMID: 31419796     DOI: 10.3171/2019.5.JNS19780

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  11 in total

1.  Prediction of lower-grade glioma molecular subtypes using deep learning.

Authors:  Yutaka Matsui; Takashi Maruyama; Masayuki Nitta; Taiichi Saito; Shunsuke Tsuzuki; Manabu Tamura; Kaori Kusuda; Yasukazu Fukuya; Hidetsugu Asano; Takakazu Kawamata; Ken Masamune; Yoshihiro Muragaki
Journal:  J Neurooncol       Date:  2019-12-21       Impact factor: 4.130

2.  Diagnostic value of PET/CT with 11C-methionine (MET) and 18F-fluorothymidine (FLT) in newly diagnosed glioma based on the 2016 WHO classification.

Authors:  Tomoya Ogawa; Nobuyuki Kawai; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

3.  Multiple positron emission tomography tracers for use in the classification of gliomas according to the 2016 World Health Organization criteria.

Authors:  Keisuke Miyake; Kenta Suzuki; Tomoya Ogawa; Daisuke Ogawa; Tetsuhiro Hatakeyama; Aya Shinomiya; Nobuyuki Kudomi; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  Neurooncol Adv       Date:  2020-12-07

4.  The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.

Authors:  Feng-Min Liu; Yu-Fei Gao; Yanyan Kong; Yihui Guan; Jinsen Zhang; Shuai-Hong Li; Dan Ye; Wenyu Wen; Chuantao Zuo; Wei Hua
Journal:  BMC Cancer       Date:  2021-01-20       Impact factor: 4.430

5.  Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma.

Authors:  Kosuke Nakajo; Takehiro Uda; Toshiyuki Kawashima; Yuzo Terakawa; Kenichi Ishibashi; Naohiro Tsuyuguchi; Yuta Tanoue; Atsufumi Nagahama; Hiroshi Uda; Saya Koh; Tsuyoshi Sasaki; Kenji Ohata; Yonehiro Kanemura; Takeo Goto
Journal:  Sci Rep       Date:  2022-01-11       Impact factor: 4.379

6.  Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma.

Authors:  Bart R J van Dijken; Alfred O Ankrah; Gilles N Stormezand; Rudi A J O Dierckx; Peter Jan van Laar; Anouk van der Hoorn
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

7.  Integrated CT Radiomics Features Could Enhance the Efficacy of 18F-FET PET for Non-Invasive Isocitrate Dehydrogenase Genotype Prediction in Adult Untreated Gliomas: A Retrospective Cohort Study.

Authors:  Weiyan Zhou; Qi Huang; Jianbo Wen; Ming Li; Yuhua Zhu; Yan Liu; Yakang Dai; Yihui Guan; Zhirui Zhou; Tao Hua
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

8.  Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas.

Authors:  Hirohito Yano; Yuka Ikegame; Kazuhiro Miwa; Noriyuki Nakayama; Takashi Maruyama; Soko Ikuta; Kazutoshi Yokoyama; Yoshihiro Muragaki; Toru Iwama; Jun Shinoda
Journal:  Cureus       Date:  2022-07-22

9.  Hypoxia and glucose metabolism assessed by FMISO and FDG PET for predicting IDH1 mutation and 1p/19q codeletion status in newly diagnosed malignant gliomas.

Authors:  Kenta Suzuki; Nobuyuki Kawai; Tomoya Ogawa; Keisuke Miyake; Aya Shinomiya; Yuka Yamamoto; Yoshihiro Nishiyama; Takashi Tamiya
Journal:  EJNMMI Res       Date:  2021-07-21       Impact factor: 3.138

Review 10.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.